Axonics, Inc.

NasdaqGS:AXNX Voorraadrapport

Marktkapitalisatie: US$3.6b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Axonics Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Ray Cohen

Algemeen directeur

US$7.4m

Totale compensatie

Percentage CEO-salaris10.9%
Dienstverband CEO11yrs
Eigendom CEO0.6%
Management gemiddelde ambtstermijn7yrs
Gemiddelde ambtstermijn bestuur5.5yrs

Recente managementupdates

Recent updates

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14
A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20
Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27
Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28
Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Nov 28
Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Axonics stock falls 5.6% after Needham downgrades rating

Oct 10

Axonics Stock Is A Buy Amid Current Capex Cycle

Sep 07

Axonics prices stock offering of 1.75M shares

Aug 03

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Aug 02
Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19
Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

We're Hopeful That Axonics (NASDAQ:AXNX) Will Use Its Cash Wisely

Sep 15
We're Hopeful That Axonics (NASDAQ:AXNX) Will Use Its Cash Wisely

Analyse CEO-vergoeding

Hoe is Ray Cohen's beloning veranderd ten opzichte van Axonics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$7mUS$800k

-US$6m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$5mUS$750k

-US$60m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$6mUS$625k

-US$80m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$1mUS$527k

-US$55m

Sep 30 2020n/an/a

-US$66m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$6mUS$500k

-US$80m

Sep 30 2019n/an/a

-US$67m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$1mUS$430k

-US$32m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$25m

Mar 31 2018n/an/a

-US$20m

Dec 31 2017US$605kUS$430k

-US$18m

Compensatie versus markt: De totale vergoeding ($USD 7.37M ) Ray } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De vergoeding van Ray is gestegen terwijl het bedrijf verliesgevend is.


CEO

Ray Cohen (65 yo)

11yrs

Tenure

US$7,369,375

Compensatie

Mr. Raymond W. Cohen, also known as Ray, is Independent Director of Kestra Medical Technologies, Inc. from July 2024. Mr. Cohen is Venture Advisor of Andera Partners. He focuses on Life Sciences.He works...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Raymond Cohen
CEO & Director11yrsUS$7.37m0.57%
$ 20.4m
Kari Keese
Chief Financial Officerless than a yearUS$3.76m0.079%
$ 2.8m
Rinda Sama
Chief Operating Officer6.2yrsUS$3.04m0.17%
$ 5.9m
John Woock
Executive VP6.3yrsUS$3.26m0.15%
$ 5.4m
Alfred Ford
Chief Commercial Officer6.9yrsUS$2.94m0.085%
$ 3.0m
Guangqiang Jiang
Chief Technology Officer11yrsgeen gegevensgeen gegevens
Neil Bhalodkar
Vice President of Investor Relationsno datageen gegevensgeen gegevens
Aaron Pettit
General Counsel & Chief Compliance Officerno datageen gegevensgeen gegevens
Michael Williamson
Senior VPno datageen gegevensgeen gegevens
Karen Noblett
Chief Medical Officer7yrsUS$651.40k0.067%
$ 2.4m
Prabodh Mathur
Chief Product Development Officer10.4yrsgeen gegevensgeen gegevens

7.0yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AXNX is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Raymond Cohen
CEO & Director11yrsUS$7.37m0.57%
$ 20.4m
Michael Carrel
Independent Chairman5.7yrsUS$250.00k0.035%
$ 1.2m
Nancy Snyderman
Independent Director5.5yrsUS$222.50k0.039%
$ 1.4m
David Demski
Independent Director3.8yrsUS$210.00k0.019%
$ 664.5k
Robert McNamara
Independent Director5.9yrsUS$227.50k0.029%
$ 1.0m
Jane Kiernan
Independent Director5.5yrsUS$225.00k0.039%
$ 1.4m
Esteban Lopez
Independent Director3.3yrsUS$215.00k0.013%
$ 459.5k

5.5yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AXNX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).